/f/125658/7246x3240/f72d1f6fc5/esc-logo-lock-up-red-pos-rgb.png){kind=logo}
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition with evolocumab decreases myocardial inflammation in individuals with acute coronary syndrome (ACS)
Event: ESC Congress 2023
Topic: Inflammation
Session: Markers of inflammation and outcomes in patients with acute coronary syndromes
Proprotein convertase subtilisin/kexin type 9 (PCSK9), platelet activation and interaction with the vascular endothelium: the impact of PCSK9 inhibition with evolocumab in acute coronary syndrome
Event: ESC Congress 2022
Topic: Thrombosis, Platelets, and Coagulation
Session: What’s new on lipids and diabetes in acute coronary syndrome
